enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. List of sulfonamides - Wikipedia

   en.wikipedia.org/wiki/List_of_sulfonamides

   List of sulfonamides; Author of The Demon Under the Microscope, a history of the discovery of the sulfa drugs; A History of the Fight Against Tuberculosis in Canada (Chemotherapy) Presentation speech, Nobel Prize in Physiology and Medicine, 1939; The History of WW II Medicine "Five Medical Miracles of the Sulfa Drugs".

3. Diabetes medication - Wikipedia

   en.wikipedia.org/wiki/Diabetes_medication

   Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.

4. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.

5. Do ‘Natural GLP-1 Supplements’ Actually Work As Well As ...

   www.aol.com/natural-glp-1-supplements-actually...

   One of the most popular GLP-1 receptor agonists is Ozempic, a semaglutide medication that's technically designed to help control blood sugar in people with type 2 diabetes.

6. Diabetic? These Foods Will Help Keep Your Blood Sugar in Check

   www.aol.com/31-foods-diabetics-help-keep...

   Apples. The original source of sweetness for many of the early settlers in the United States, the sugar from an apple comes with a healthy dose of fiber.

7. Dipeptidyl peptidase-4 inhibitor - Wikipedia

   en.wikipedia.org/wiki/Dipeptidyl_peptidase-4...

   A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.